ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VRCA Verrica Parmaceuticals Inc

8.35
-0.70 (-7.73%)
After Hours
Last Updated: 16:30:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 248,251
Bid Price 8.00
Ask Price 8.96
News -
Day High 9.16

Low
2.86

52 Week Range

High
11.41

Day Low 8.26
Company Name Stock Ticker Symbol Market Type
Verrica Parmaceuticals Inc VRCA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.70 -7.73% 8.35 16:30:00
Open Price Low Price High Price Close Price Prev Close
9.10 8.26 9.16 8.35 9.05
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,590 248,251 $ 8.82 $ 2,190,188 - 2.86 - 11.41
Last Trade Time Type Quantity Stock Price Currency
16:07:30 44 $ 8.35 USD

Verrica Parmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
355.04M 42.42M - 5.12M -67M -1.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Verrica Parmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VRCA Message Board. Create One! See More Posts on VRCA Message Board See More Message Board Posts

Historical VRCA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.979.67478.268.84182,927-0.62-6.91%
1 Month6.8811.416.548.21282,4421.4721.37%
3 Months5.8611.414.607.11195,1802.4942.49%
6 Months3.6611.413.536.19653,8004.69128.14%
1 Year5.8411.412.865.86471,8682.5142.98%
3 Years11.4014.7891.775.68269,373-3.05-26.75%
5 Years8.6418.671.776.71197,070-0.29-3.36%

Verrica Parmaceuticals Description

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.